Bucladesine sodium salt

• CAT Number: I002213
• CAS Number: 16980-89-5
• Molecular Formula: C18H23N5O8P • Na
• Molecular Weight: 491.4
• Purity: ≥95%
• Target: cAMP
• Solubility: H2O: 40 mg/mL
• Storage: Store at -20°C
• InChIKey: KRBZRVBLIUDQNG-JBVYASIDSA-M

Bucladesine sodium salt (CAT: I002213), also known as di-butyryl cyclic adenosine monophosphate (db-cAMP), is a cell-permeable analog of cyclic adenosine monophosphate (cAMP). It acts as a potent activator of protein kinase A (PKA) and mimics the intracellular effects of cAMP. The bucladesine sodium salt is commonly used in research to study the role of cAMP signaling pathways in various cellular processes. It has been investigated for its potential therapeutic applications in cardiovascular diseases, neurodegenerative disorders, and cancer. The bucladesine sodium salt is a valuable tool for understanding cAMP-mediated signaling and its impact on cellular physiology and disease processes.

Reference

[1]. Sharifzadeh, M., et al., Post-training intrahippocampal infusion of nicotine-bucladesine combination causes a synergistic enhancement effect on spatial memory retention in rats. Eur J Pharmacol, 2007. 562(3): p. 212-20.
[2]. Azami, K., et al., The quantitative evaluation of cholinergic markers in spatial memory improvement induced by nicotine-bucladesine combination in rats. Eur J Pharmacol, 2010. 636(1-3): p. 102-7.
[3]. Mafune, E., M. Takahashi, and N. Takasugi, Effect of vehicles on percutaneous absorption of bucladesine (dibutyryl cyclic AMP) in normal and damaged rat skin. Biol Pharm Bull, 1995. 18(11): p. 1539-43.
[4]. Rundfeldt, C., et al., The stable cyclic adenosine monophosphate analogue, dibutyryl cyclo-adenosine monophosphate (bucladesine), is active in a model of acute skin inflammation. Arch Dermatol Res, 2012.